Janssen

DARZALEX FASPRO

Manufacturer:

Janssen

Darzalex Faspro HCPCS:

J9144

HCPCS Code Descriptor:

Injection, daratumumab, 10 mg and hyaluronidase-fihj

Category:

J Code

Darzalex Faspro NDCs:

57894-0503-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Darzalex Faspro CPT Codes:

Potential CPT administration codes for Darzalex Faspro can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Darzalex Faspro:

DARZALEX FASPRO is an Oncology drug manufactured by Janssen and administered via the Subcutaneous route of administration. The J Code: J9144 is aligned to the drug DARZALEX FASPRO.

ACCESS PRICING AND MORE BY REGISTERING

J9144 Added Date:

January 1, 2021

J9144 Effective Date:

January 1, 2021

J9144 Termination Date:

HCPCS Active

Darzalex Faspro billing and coding information can be found through Janssen at the link below:
Darzalex Faspro patient assistance information can be found through Janssen Compass at the URL: https://www.darzalex.com/patient-and-care-partner-support
DARZALEX FASPRO prescribing information can be found at the link below:
Information regarding DARZALEX FASPRO’s side effects can be found at MedlinePlus